Carmen Andreescu

Carmen Andreescu

Auto-generated profile, based on publicly available information

Carmen Andreescu

Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2013 in Psychiatry Research: Neuroimaging
Verified
Journal Article
Closed access
CACarmen Andreescu
Carmen Andreescu
DTDana L. Tudorascu
Dana L. Tudorascu
MBMeryl A. Butters
Meryl A. Butters
ETErica Tamburo
Erica Tamburo
MPMeenal Patel
Meenal Patel
HAHoward Aizenstein
Howard Aizenstein

31 January 2020
Verified
Book Chapter
Closed access
PDF file
CACarmen Andreescu
Carmen Andreescu
SLSoyoung Lee
Soyoung Lee

29 June 2020 in Human Brain Mapping
Verified
Journal Article
Open access
PDF file
AZAndré Zugman
André Zugman
AHAnita Harrewijn
Anita Harrewijn
ECElise M. Cardinale
Elise M. Cardinale
HZHannah Zwiebel
Hannah Zwiebel
GFGabrielle F. Freitag
Gabrielle F. Freitag
AWAnderson Winkler
Anderson Winkler
The ENIGMA group on Generalized Anxiety Disorder (ENIGMA‐Anxiety/GAD) is part of a broader effort to investigate anxiety disorders using imaging and genetic data across multiple sites worldwide. The group is actively conducting a mega‐analysis of a large number of brain structural scans. In this process, the group was confronted with many methodological challenges related to study planning and implementation, between‐country transfer of subject‐level data, quality control of a considerable amount of imaging data, and choices related to statistical methods and efficient use of resources. This report summarizes the background information and rationale for the various methodological decisions, as well as the approach taken to implement them. The goal is to document the approach and help guide other research groups working with large brain imaging data sets as they develop their own analytic pipelines for mega‐analyses.

20 January 2021 in Neurobiology of Aging
Verified
Journal Article
Closed access
HKHelmet Karim
Helmet Karim
MLMaria Ly
Maria Ly
GYGary Yu
Gary Yu
RKRobert Krafty
Robert Krafty
DTDana L. Tudorascu
Dana L. Tudorascu
CACarmen Andreescu
Carmen Andreescu

25 April 2024 in Molecular Psychiatry
Verified
Journal Article
Open access
PDF file
AKA. Kolobaric
A. Kolobaric
CAC. Andreescu
C. Andreescu
EJE. Jašarević
E. Jašarević
CHC. H. Hong
C. H. Hong
HRH. W. Roh
H. W. Roh
SSSang Joon Son
Sang Joon Son
Depression in older adults with cognitive impairment increases progression to dementia. Microbiota is associated with current mood and cognition, but the extent to which it predicts future symptoms is unknown. In this work, we identified microbial features that reflect current and predict future cognitive and depressive symptoms. Clinical assessments and stool samples were collected from 268 participants with varying cognitive and depressive symptoms. Seventy participants underwent 2-year follow-up. Microbial community diversity, structure, and composition were assessed using high-resolution 16 S rRNA marker gene sequencing. We implemented linear regression to characterize the relationship between microbiome composition, current cognitive impairment, and depressive symptoms. We leveraged elastic net regression to discover features that reflect current or future cognitive function and depressive symptoms. Greater microbial community diversity associated with lower current cognition in the whole sample, and greater depression in participants not on antidepressants. Poor current cognitive function associated with lower relative abundance of Bifidobacterium, while greater GABA degradation associated with greater current depression severity. Future cognitive decline associated with lower cognitive function, lower relative abundance of Intestinibacter, lower glutamate degradation, and higher baseline histamine synthesis. Future increase in depressive symptoms associated with higher baseline depression and anxiety, lower cognitive function, diabetes, lower relative abundance of Bacteroidota, and lower glutamate degradation. Our results suggest cognitive dysfunction and depression are unique states with an overall biological effect detectable through gut microbiota. The microbiome may present a noninvasive readout and prognostic tool for cognitive and psychiatric states.

30 December 2013 in Journal of Geriatric Psychiatry and Neurology
Verified
Journal Article
Closed access
PDF file
HAHoward J. Aizenstein
Howard J. Aizenstein
AKAlexander Khalaf
Alexander Khalaf
SWSarah E. Walker
Sarah E. Walker
CACarmen Andreescu
Carmen Andreescu
In older adults, depression not only results in more years lived with disability than any other disease but it also carries additional risks of suicide, medical comorbidities, and family caregiving burden. Because it can take many months to identify an effective treatment regimen, it is of utmost importance to shorten the window of time and identify early on what medications and dosages will work effectively for individuals having depression. Late-life depression (LLD) has been associated with greater burden of age-related changes (eg, atrophy, white matter ischemic changes, and functional connectivity). Depression in midlife has been shown to alter affective reactivity and regulation, and functional magnetic resonance imaging (fMRI) studies in LLD have replicated the same abnormalities. Effective treatment can normalize these alterations. This article provides a review of the current literature using structural and functional neuroimaging to identify MRI predictors of treatment response in LLD. The majority of the literature on structural MRI has focused on the vascular depression hypothesis, and studies support the view that loss of brain volume and white matter integrity was associated with poorer treatment outcomes. Studies using fMRI have reported that lower task-based activity in the prefrontal cortex and limbic regions was associated with poorer outcome. These imaging markers may be integrated into clinical decision making to attain better treatment outcomes in the future.